Sign in
Taking people in United StatesNo phase

Studies how type 1 diabetes may raise heart attack and stroke risk

Compares fat particle handling in adults with type 1 diabetes and healthy volunteers.

Key facts

Who runs it
University of Missouri-Columbia
Where
Columbia, United StatesSee the site
Trial code
Registry title
Lipoprotein Kinetics in T1D
Status
Recruiting
People taking part
30 people, planned
Started
9 May 2022
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metabolic testing
Record updated
10 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 45 with type 1 diabetes, and healthy adults as a comparison group. It studies how type 1 diabetes raises the risk of heart attack and stroke.

Age
18 to 45 years
Sex
Women and men can join.
Disease stage
Type 1 diabetes with HbA1c below 8.0% (64 mmol/mol), or healthy control participants. Body mass index 18.5 to below 30.0 kg/m2. Fasting triglyceride below 150 mg/dL (1.7 mmol/L).
Earlier treatment
People with type 1 diabetes need a stable insulin routine for at least 8 weeks before screening and no diabetes medicine other than insulin.
Biomarker or test result
Healthy controls need fasting plasma glucose below 100 mg/dL (5.6 mmol/L), glucose 2 hours after a 75 g glucose drink below 140 mg/dL (7.8 mmol/L), and HbA1c below 5.6% (38 mmol/mol).

Main reasons for not taking part

  • More than 1.5 hours of structured exercise a week
  • Tobacco use, excessive alcohol, or supplements or medicines that affect fat metabolism
  • Thyroid problems or other disorders that affect fat metabolism
  • Pregnant or breastfeeding women, or women who are not premenopausal with regular periods
  • Severe low blood sugar with seizure or needing help in the 6 months before screening (type 1 diabetes group)

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age: ≥18 but ≤45 years
  • premenopausal/eumenorrheic and not pregnant or breastfeeding
  • non-obese (body mass index ≥18.5<30.0 kg/m2)
  • Fasting plasma triglyceride <150 mg/dL; Additional inclusion criteria for control subjects:
  • Fasting plasma glucose <100 mg/dL
  • Plasma glucose 2 h after a 75 g oral glucose challenge <140 mg/dL
  • HbA1c <5.6%; Additional inclusion criteria for subjects with T1DM:
  • stable insulin regimen (multiple daily insulin injections or continuous subcutaneous insulin) for at least 8 weeks before screening
  • no use of diabetes medications other than insulin
  • HbA1c <8.0%, basal (overnight fasted)
  • no severe symptomatic hypoglycemic event associated with a seizure or requiring help from other people or a medical facility in the 6 months prior to screening or metabolic testing

Who cannot take part

  • use of tobacco products, excessive amounts of alcohol, or dietary supplements and/or medications known to affect lipid metabolism
  • hypothyroidism or other disorders known to affect lipid metabolism
  • conditions that would make it impossible to complete the study protocol
  • more than 1.5 h of structured exercise/week

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

Where in United States

  • University of Missouri School of MedicineColumbia, United StatesContact: Bettina Mittendorfer, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.

The 2 groups in the trial

  • Control groupOther group

    Healthy control group

    Treatment: Metabolic testing

  • T1D groupExisting treatment, for comparison

    Treatment: Metabolic testing

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Apolipoprotein C3-loading of Apolipoprotein B100 Lipoproteins and Cardiovascular Disease in Patients With Type 1 Diabetes
Plain-language title
Studies how type 1 diabetes may raise heart attack and stroke riskGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05179954, who can take part
Record updated
10 February 2026